CORRESP Filing
PLUS THERAPEUTICS, INC.
Date: Aug. 12, 2025 · CIK: 0001095981 · Accession: 0001193125-25-179175
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289526
Letter
Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 filed on August 12, 2025 File No. 333-289526 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement, as amended, so that it becomes effective as of 5:30 p.m. Eastern Time on Thursday, August 14, 2025, or as soon thereafter as possible. [Signature Page to Follow]
August 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
Plus Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 filed on August 12, 2025 File No. 333-289526 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement, as amended, so that it becomes effective as of 5:30 p.m. Eastern Time on Thursday, August 14, 2025, or as soon thereafter as possible. [Signature Page to Follow] Very truly yours, Plus Therapeutics, Inc. By: /s/ Andrew Sims Name: Andrew Sims Title: Chief Financial Officer cc: Aaron M. Schleicher, Sullivan & Worcester LLP [Signature Page to Acceleration Request]